Strait of Hormuz Oil Shipments Hit Six-Month High as U.S. Clears Mines 
Bessent, He Lifeng to Discuss AI Security and Trade in New York 
Vietnam, US Trade Deal Could Be Signed Soon, To Lam Says 
Petrobras Joins Brazil Diesel Subsidy Program 
Canada Eyes India Trade Deal by Year-End 
NASA, Boeing Discuss Expanding Starliner Missions 
Bolivia Approves $1.9 Billion IMF Financing Deal 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
OpenAI Urges US-Led Global Standards for Frontier AI 
U.S. Dollar Hits Eight-Week High After Fed Rate Hike 
Japan, U.S. Discuss $19 Billion GlobalFoundries Chip Plant 
Fed Rate Hike Threatens Housing as U.S. Growth Leans on AI, Citi Says 
Apple Pay Set for India Launch With Axis Bank 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
Vietnam Stocks Join FTSE Emerging Market Indexes, Unlocking Billions in Foreign Investment 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
Add as a preferred source on Google
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
